Article

Targeted but Troubling: CYP450 Inhibition by Kinase and PARP Inhibitors and Its Clinical Implications

2025-05-26

Abstract excerpt

Cytochrome P450 (CYP450) enzymes are pivotal in the metabolism of numerous anticancer agents, with CYP3A4 being the predominant isoform involved. Inhibition of CYP450 enzymes is a major mechanism underlying clinically significant drug-drug interactions (DDIs), particularly in oncology, where polypharmacy is frequent. This review aims to provide a comprehensive and critical overview of CYP450 enzyme inhibition, foc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bd6244c0-d0ac-56ea-b994-93d74958b452
DOI: 10.3390/ddc4020024

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeted but Troubling: CYP450 Inhibition by Kinase and PARP Inhibitors and Its Clinical ImplicationsDOI 10.3390/ddc4020024Read

The kinase polypharmacology landscape of clinical PARP inhibitorsSemantic proximity Read

Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer TherapySemantic proximity Read

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological ConditionsSemantic proximity Read

Contributing factors on metabolic mechanism-based CYP3A4-activated/deactivated anticancer drugs: implications for individualizing chemotherapySemantic proximity Read

Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy.Semantic proximity Read

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.Semantic proximity Read

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and RibociclibSemantic proximity Read

[A review: drug-drug interactions of epithelial growth factor receptor-tyrosine kinase inhibitors].Semantic proximity Read

Development and characterization of pFluor50, a fluorogenic-based kinetic assay system for high-throughput inhibition screening and characterization of time-dependent inhibition and inhibition type for six human CYPsSemantic proximity Read

Delineating Drug Class and Target-Specific Adverse Events of Kinase InhibitorsSemantic proximity Read

Disparities in dosing, drug reduction, and drug discontinuation among US FDA approved tyrosine kinase inhibitorsSemantic proximity Read

Spectrum and Degree of CDK Drug Interactions Predicts Clinical PerformanceSemantic proximity Read